

BoNT

Cat.No. 158 002; Polyclonal rabbit antibody, 200 µl antiserum (lyophilized)

Data Sheet

Reconstitution/ Storage	200 µl antiserum, lyophilized. For reconstitution add 200 µl H ₂ O, then aliquot and store at -20°C until use.
Applications	WB: 1 : 1000 up to 1 : 10000 (AP staining) IP: not tested yet ICC: not tested yet IHC: not tested yet IHC-P/FFPE: not tested yet
Immunogen	Recombinant protein corresponding to AA 1 to 422 from Clostridium botulinum BoNT (UniProt Id: Q00496)
Specificity	Specific for BoNT E.

TO BE USED IN VITRO / FOR RESEARCH ONLY
NOT TOXIC, NOT HAZARDOUS, NOT INFECTIOUS, NOT CONTAGIOUS

The neurotoxins of Clostridium botulinum **BoNTs** belong to the most potent protein toxins. These Zinc proteases elicit paralysis by cleaving SNARE proteins like SNAP 25, Syntaxin 1 and Synaptobrevin which mediate the fusion of synaptic vesicles with the presynaptic membrane.

There are seven known serotypes of BoNTs (A to G) with different cleavage properties. BoNTs are translated as ~150 kDa single-chain, non-toxic precursor proteins which are cleaved into a catalytic light chain (LC) and a heavy translocation chain (HCT).

Selected General References

The synaptic vesicle protein 2C mediates the uptake of botulinum neurotoxin A into phrenic nerves.
Mahrhold S, Rummel A, Bigalke H, Davletov B, Binz T
FEBS letters (2006) 580(8): 2011-4.

SV2 is the protein receptor for botulinum neurotoxin A.
Dong M, Yeh F, Tepp WH, Dean C, Johnson EA, Janz R, Chapman ER
Science (New York, N.Y.) (2006) 312(5773): 592-6.

Structure of botulinum neurotoxin type D light chain at 1.65 Å resolution: repercussions for VAMP-2 substrate specificity.
Arndt JW, Chai Q, Christian T, Stevens RC
Biochemistry (2006) 45(10): 3255-62.

Unique substrate recognition by botulinum neurotoxins serotypes A and E.
Chen S, Barbieri JT
The Journal of biological chemistry (2006) 281(16): 10906-11.

Pharmacology of botulinum toxin: differences between type A preparations.
Rosales RL, Bigalke H, Dressler D
European journal of neurology (2006) 13 Suppl 1: 2-10.

Sensitive detection of botulinum neurotoxin types C and D with an immunoaffinity chromatographic column test.
Gessler F, Hampe K, Böhnel H
Applied and environmental microbiology (2005) 71(12): 7897-903.

Sequence variation within botulinum neurotoxin serotypes impacts antibody binding and neutralization.
Smith TJ, Lou J, Geren IN, Forsyth CM, Tsai R, Laporte SL, Tepp WH, Bradshaw M, Johnson EA, Smith LA, Marks JD, et al.
Infection and immunity (2005) 73(9): 5450-7.

Synaptic vesicle chips to assay botulinum neurotoxins.
Ferracci G, Miquelis R, Kozaki S, Seagar M, Lévêque C
The Biochemical journal (2005) 391(Pt 3): 659-66.

New insights into clostridial neurotoxin-SNARE interactions.
Breidenbach MA, Brunger AT
Trends in molecular medicine (2005) 11(8): 377-81.

Botulinum neurotoxins: revival of an old killer.
Montecucco C, Molgó J
Current opinion in pharmacology (2005) 5(3): 274-9.

Structural analysis of botulinum neurotoxin type E catalytic domain and its mutant Glu212-->Gln reveals the pivotal role of the Glu212 carboxylate in the catalytic pathway.
Agarwal R, Eswaramoorthy S, Kumaran D, Binz T, Swaminathan S
Biochemistry (2004) 43(21): 6637-44.